

## Cuvitru

Qatar · access guide

# How to access Cuvitru for primary immunodeficiency from Qatar: 2026 pathway via HMC adult and Sidra Medicine paediatric allergy-immunology | Reserve Meds

By Reserve Meds clinical & regulatory team. Last reviewed 2026-05-20.

Qatar manages PI patients through HMC adult allergy-immunology and Sidra Medicine paediatric immunology. Sidra runs the regional paediatric immunodeficiency service of record. The 2026 question is whether to convert selected patients to weekly SC Cuvitru under MoPH named-patient import.

## Why Cuvitru, why now

Cuvitru is subcutaneous immune globulin 20% for primary humoral immunodeficiency in adults and paediatric patients aged 2 and older. Self-administered weekly. Useful for poor venous access, IVIG wear-off, or schedule-incompatible monthly infusion.

Reserve Meds does not promote one IgG product over another. Alternatives include Hyqvia, Octagam, Gammagard, Privigen, and others.

## What Cuvitru is, in plain language

20% IgG liquid injected under the skin at abdomen or thigh, once weekly. Self-administered at home after training. Pump-driven 60-90 minutes. Steady-state IgG after several weeks.

## Eligibility at a Qatar allergy-immunology clinic

Required: confirmed PI with documented IgG deficiency, impaired specific antibody response, or genetic confirmation. Self-administration capability. IgG trough goal established. Paediatric cases at Sidra (where most regional confirmation flows); adult at HMC.

## The Qatar prescribing and supply picture

Cuvitru is not currently MoPH-registered. Access via MoPH named-patient personal-import filed through HMC or Sidra pharmacy. Cold chain required. Reserve Meds coordinates the import file, prescription chain, and shipping.

## Cost band

---

USD 75K-110K annual per patient (QAR 275K-400K), weight-and-dose dependent. MoPH coverage for Qatari nationals under PI rare-disease provision case-by-case; private insurance covers IVIG/SCIG with pre-authorization.

## What to expect, week-by-week

---

Weeks 0 to 2: MoPH import filing, prescription, training arrangement. Weeks 2 to 4: shipment arrives, clinic-supervised SC training. Weeks 4 to 16: weekly SC at home; IgG trough at week 12. Month 6 and 12: full reassessment, infection log review, dose adjustment.

## When Cuvitru is the wrong drug

---

Good venous access and no self-injection appetite: IVIG. Unable to reliably self-administer: IVIG safer. Hard to achieve trough weekly: consider larger less-frequent SC dosing (competing product). Reserve Meds does not promote one IgG over another.

## Closing

---

Reserve Meds runs the Cuvitru import file from the HMC adult or Sidra paediatric allergy-immunology referral through MoPH named-patient authorisation and delivered cold-chain supply. Clinical decisions remain with your treating allergist-immunologist.

### ***Reserve Meds's role***

US-based concierge coordinator for cross-border specialty medicine. We are not the prescriber, not the dispensing pharmacy, and not the manufacturer. All clinical decisions remain with your treating physician.

---

### **Reserve Meds**

*reserved for you.*

Composite case examples. This document is for general information only and does not constitute medical advice. Please consult your treating physician.

Reserve Meds is in pre-launch. Published timelines and cost ranges are indicative, not guarantees.

reservemeds.com · hello@reservemeds.com